Obesity drug sales surge at Novo Nordisk
Sales of Novo Nordisk’s obesity drugs, such as Wegovy, rose by more than 50 per cent last year, helping send shares in Europe ...
Business Insider1mon
Novo Nordisk’s Strategic Acquisition of Catalent: Short-term Challenges but Long-term Growth Potential with a Buy Recommendation
and streamline your search for investment opportunities using Tipranks' Stock Screener Michael Nedelcovych’s rating is based on Novo Nordisk’s strategic acquisition of Catalent, which ...
Hosted on MSN1y
Weight-loss drug maker Novo Nordisk's profit surges as sales boom
Danish pharmaceutical giant Novo Nordisk posted bumper profits ... "We continue to make progress on our strategic aspirations. Our focus in 2024 will be on reaching more patients, progressing ...
Yahoo Finance28d
IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases
today announced a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions. The partnership will ...
The Bakersfield Californian28d
IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral ...
today announced a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions. The partnership will ...